Smithfield Trust Co. Has $3.69 Million Holdings in Pfizer Inc. (PFE)

Share on StockTwits

Smithfield Trust Co. raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 101,660 shares of the biopharmaceutical company’s stock after acquiring an additional 3,444 shares during the quarter. Smithfield Trust Co.’s holdings in Pfizer were worth $3,688,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the business. Wendell David Associates Inc. grew its position in Pfizer by 2.4% in the second quarter. Wendell David Associates Inc. now owns 57,613 shares of the biopharmaceutical company’s stock worth $2,090,000 after acquiring an additional 1,363 shares in the last quarter. Chesley Taft & Associates LLC grew its position in Pfizer by 0.7% in the second quarter. Chesley Taft & Associates LLC now owns 221,682 shares of the biopharmaceutical company’s stock worth $8,043,000 after acquiring an additional 1,432 shares in the last quarter. Gamco Investors INC. ET AL grew its position in Pfizer by 0.4% in the first quarter. Gamco Investors INC. ET AL now owns 387,501 shares of the biopharmaceutical company’s stock worth $13,752,000 after acquiring an additional 1,470 shares in the last quarter. Quadrant Private Wealth Management LLC grew its position in Pfizer by 6.5% in the first quarter. Quadrant Private Wealth Management LLC now owns 24,376 shares of the biopharmaceutical company’s stock worth $865,000 after acquiring an additional 1,494 shares in the last quarter. Finally, Callahan Advisors LLC boosted its position in Pfizer by 0.5% during the first quarter. Callahan Advisors LLC now owns 293,220 shares of the biopharmaceutical company’s stock valued at $10,406,000 after buying an additional 1,503 shares during the period. 69.12% of the stock is currently owned by institutional investors and hedge funds.

Pfizer stock opened at $41.78 on Friday. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41. The stock has a market cap of $249.13 billion, a PE ratio of 14.58, a PEG ratio of 2.01 and a beta of 0.96. Pfizer Inc. has a 1-year low of $33.20 and a 1-year high of $42.77.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.07. The company had revenue of $13.47 billion during the quarter, compared to analyst estimates of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. Pfizer’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.67 earnings per share. sell-side analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 4th. Stockholders of record on Friday, August 3rd were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, August 2nd. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.26%. Pfizer’s dividend payout ratio is currently 51.32%.

Several analysts have issued reports on the stock. Goldman Sachs Group restated a “neutral” rating and set a $45.00 price target on shares of Pfizer in a research report on Tuesday, August 28th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Thursday, June 7th. They set an “overweight” rating and a $45.00 price target for the company. Credit Suisse Group upped their price target on shares of Pfizer from $39.00 to $40.00 and gave the company a “neutral” rating in a research report on Wednesday, August 1st. Jefferies Financial Group restated a “neutral” rating and set a $39.00 price target on shares of Pfizer in a research report on Monday, May 14th. Finally, Morgan Stanley set a $45.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Thursday. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $41.74.

In other news, CEO Ian C. Read sold 486,753 shares of the stock in a transaction dated Monday, July 16th. The shares were sold at an average price of $37.36, for a total transaction of $18,185,092.08. Following the completion of the sale, the chief executive officer now directly owns 1,145,693 shares in the company, valued at $42,803,090.48. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Laurie J. Olson sold 10,214 shares of the stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $41.00, for a total transaction of $418,774.00. Following the sale, the insider now owns 72,672 shares of the company’s stock, valued at $2,979,552. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 761,230 shares of company stock valued at $29,054,690. 0.06% of the stock is currently owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Story: Market Capitalization

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply